BioPorto A/S (CPH:BIOPOR)
1.195
+0.045 (3.91%)
Sep 4, 2026, 4:59 PM CET
BioPorto Revenue
BioPorto had revenue of 6.90M DKK in the quarter ending June 30, 2026, a decrease of -34.83%. This brings the company's revenue in the last twelve months to 38.37M, up 7.06% year-over-year. In the year 2025, BioPorto had annual revenue of 40.29M with 11.16% growth.
Revenue (ttm)
38.37M
Revenue Growth
+7.06%
P/S Ratio
15.42
Revenue / Employee
872.02K
Employees
44
Market Cap
591.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.29M | 4.04M | 11.16% |
| Dec 31, 2024 | 36.24M | 5.29M | 17.07% |
| Dec 31, 2023 | 30.96M | 1.99M | 6.87% |
| Dec 31, 2022 | 28.97M | 4.72M | 19.44% |
| Dec 31, 2021 | 24.25M | 1.05M | 4.53% |
| Dec 31, 2020 | 23.20M | -3.42M | -12.84% |
| Dec 31, 2019 | 26.62M | 606.00K | 2.33% |
| Dec 31, 2018 | 26.02M | 861.00K | 3.42% |
| Dec 31, 2017 | 25.16M | 4.44M | 21.40% |
| Dec 31, 2016 | 20.72M | 337.00K | 1.65% |
| Dec 31, 2015 | 20.38M | 1.68M | 8.97% |
| Dec 31, 2014 | 18.71M | 2.08M | 12.51% |
| Dec 31, 2013 | 16.63M | -1.23M | -6.90% |
| Dec 31, 2012 | 17.86M | -726.00K | -3.91% |
| Dec 31, 2011 | 18.58M | 4.78M | 34.65% |
| Dec 31, 2010 | 13.80M | 2.79M | 25.38% |
| Dec 31, 2009 | 11.01M | 1.13M | 11.47% |
| Dec 31, 2008 | 9.88M | 1.54M | 18.41% |
| Dec 31, 2007 | 8.34M | 2.79M | 50.16% |
| Dec 31, 2006 | 5.55M | 1.19M | 27.33% |
| Dec 31, 2005 | 4.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 329.43B |
| Coloplast | 28.44B |
| Genmab | 27.03B |
| Demant | 24.63B |
| ChemoMetec | 493.12M |
| Gubra | 271.02M |
| Scandinavian Medical Solutions | 214.99M |
| Stenocare | 11.52M |
BioPorto News
- 17 days ago - BioPorto Quarterly report: Q2 2026 - Filings
- 17 days ago - BioPorto Slides: Q2 2026 - Filings
- 17 days ago - BioPorto Reports Underlying NGAL Growth; Advances U.S. Adult Regulatory Pathway - Nasdaq
- 2 months ago - Grant of Warrants - GlobeNewsWire
- 2 months ago - BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback - GlobeNewsWire
- 3 months ago - BioPorto Earnings release: Q1 2026 - Filings
- 3 months ago - BioPorto Slides: Q1 2026 - Filings
- 3 months ago - BioPorto announces Interim Result for the First Quarter of 2026 - GlobeNewsWire